meclidinium bromide added onto fluticasone furoate/ vilanterol in COPD - Study 2
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- EUCTR2013-002239-44-DE
- Lead Sponsor
- GlaxoSmithKline Research & Development Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 600
1.Type of subject: Outpatient.
2.Informed Consent: A signed and dated written informed consent prior to study participation.
3.Age: Subjects 40 years of age or older at Visit 1.
4.Gender: Male or female subjects.
A female is eligible to enter and participate in the study if she is of:
Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, > 45 years, in the absence of hormone replacement therapy.
OR
Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study – screening to follow-up contact):
•Abstinence
•Oral Contraceptive, either combined or progestogen alone
•Injectable progestogen
•Implants of levonorgestrel
•Estrogenic vaginal ring
•Percutaneous contraceptive patches
•Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
•Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, documented” refers to the outcome of the investigator's/designee’s medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records.
•Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
5.Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
6.Smoking History: Current or former cigarette smokers with a history of cigarette smoking of at least 10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack year history.
7.Severity of Disease: A pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and a pre and post-albuterol/salbutamol FEV1 of 70% or less than 70% of predicted normal values at Visit 1 (Screening) calculated using Nutrition Health and Examination Survey (NHANES) III reference equations [Hankinson, 1999; Hankinson, 2010].
8.Dyspnea: A score of =2 on the mMRC Dyspnea Scale at Visit 1.
9.QTc Criteria:
QTc(F) <450msec or
QTc(F) <480msec for patients with QRS duration >120msec
The QTc is the QT interval corrected for heart rate according to either Bazett’s formula (QTcB), Fridericia’s formula (QTcF), or another method, machine or manual overread.
•For subject eligibility and withdrawal, QTcF will be used.
•For purposes of data analysis, QTcF will be used as primary.
The QTc should be
1.Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
2.Asthma: A current diagnosis of asthma.
3.Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to COPD should be excluded. Examples may include clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
4.Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for <5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
5.Contraindications: Any history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, corticosteroid (intranasal, inhaled or systemic) lactose/milk protein or magnesium stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction, that, in the opinion of the study physician contraindicates study participation or use of an inhaled LAMA, LABA or ICS.
6.Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
7.Lower respiratory tract infection: Subjects with lower respiratory tract infection that required the use of antibiotics within 6 weeks prior to Visit 1.
8.Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
9.12-Lead ECG: An abnormal and clinical significant ECG finding from the 12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix 4. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 4.
10.Clinically significant and abnormal laboratory finding at Screening (Visit1). After discussion with the Medical Monitor, the investigator may have the option to verify the abnormal lab result prior to Visit2
11.Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
12.Excluded Medications: Use of the medications listed in Table 1 of the study protocol (page 23) are not permitted within the defined time intervals prior to Visit 1and throughout the study.
13.Prior enrolment in one of the replicate studies: subjects who have previously been assigned a subject number (enrolled) in study 200109 that is a replicate study of 200110.
14.Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., 12 hours or l
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective is to evaluate the efficacy and safety of the addition of UMEC 125 mcg to FF/VI 100/25 mcg once-daily and the addition of UMEC 62.5 mcg to FF/VI 100/25 mcg once-daily, compared with placebo plus FF/VI 100/25 once-daily over 12 weeks in subjects with COPD.;Secondary Objective: The secondary objective is to evaluate the addition of UMEC 125 mcg to FF/VI 100/25 mcg once-daily and the addition of UMEC 62.5 mcg to FF/VI 100/25 mcg once-daily, compared with placebo plus FF/VI 100/25 once-daily on COPD-related health status assessments over 12 weeks in subjects with COPD.;Primary end point(s): Trough Forced Expiratory Volume in One Second (FEV1) on Day 85<br>Trough FEV1 on Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes pre-dose on Treatment Day 1.<br>;Timepoint(s) of evaluation of this end point: Day 85
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Weighted mean (WM) 0-6 hour FEV1 obtained post-dose on Day 84 (Week 12);Timepoint(s) of evaluation of this end point: Day 84